Maxim Group Upgrades VolitionRx Limited to Buy
Maxim Group reinstates VolitionRx Limited with a Buy rating and a $4 price target.
Key Points
- Maxim Group has reinstated VolitionRx Limited with a Buy rating and set a price target of $4.
- VolitionRx shares are trading around $1.43, with a 52-week range between $1.3 and $18.8.
- Insiders have sold shares recently, while institutional investors like Lagoda Investment Management have reduced their holdings.
Maxim Group has reinstated its coverage on VolitionRx Limited, trading under the ticker VNRX on the NYSE American, with a Buy rating. Analyst Michael Okunewitch set a price target of $4 on June 18, 2026. This move highlights a positive outlook for the company as it currently trades around $1.43 per share.
VolitionRx Limited Stock Snapshot
Shares of NYSE American:VNRX are trading near $1.43. VolitionRx Limited has a market cap of about $16.57 million. The stock has a 52-week low of $1.3 and a high of $18.8. Its 50-day moving average is $2.46, while the 200-day moving average stands at $5.85. The current ratio is 0.333, indicating limited short-term liquidity, and the quick ratio is 0.247.
Other Institutional Activity in VolitionRx Limited
Lagoda Investment Management, L.P. significantly reduced its holdings in VolitionRx, cutting down by 10.65 million shares to hold 807,450 shares worth approximately $3.26 million. Geode Capital Management, LLC also reduced its position by 902,482 shares, ending with 61,504 shares valued at $248,510. On the other hand, Vanguard Capital Management LLC and Luminus Management LLC each established positions, holding 50,684 and 49,750 shares valued at $204,762 and $200,990, respectively.
Insider Buying and Selling at VolitionRx Limited
Recent insider activity at VolitionRx shows several executives selling shares in March 2026. Nicholas Plummer, GC at Volition Diagnostics, sold 7,003 shares on March 17, while Chief Scientific Officer Jacob Vincent Micallef sold 5,310 shares on the same day. Other insiders, including Secretary Rodney Gerard Rootsaert and Chief Commercial Officer Gael Forterre, also sold shares.
Analysts Set New Price Targets
On June 18, 2026, Maxim Group reinstated VolitionRx with a Buy rating and a $4 price target. Previously, HC Wainwright & Co. maintained a Buy rating with a $1 target on April 2, 2026. D. Boral Capital has consistently maintained a Buy rating with targets ranging from $3 to $5 over the past months. The consensus target price is $20.21, based on four analyst opinions.
About VolitionRx Limited
VolitionRx Limited is a healthcare company specializing in medical devices, headquartered in Henderson, Nevada. It develops blood tests for cancer detection and monitoring, including the Nu.Q Vet for animals and Nu.Q Nets for diseases like sepsis. The company also offers solutions like Nu.Q Discover for profiling nucleosomes and Capture-PCR for isolating tumor-derived DNA. Under the leadership of CEO Cameron Reynolds, VolitionRx employs 67 people.
Bottom Line
Maxim Group's Buy rating and $4 target suggest optimism for VolitionRx's future. Investors watch these ratings closely, though it's important to remember that analyst opinions are just one piece of the puzzle. As a reminder, these insights are backward-looking and reflect the analysts' perspective as of their issuing dates.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.